Cyclohexanols

Mineral Ice® Expands its Portfolio with Maximum Strength Quick Dry Pain-Relieving Foam

Retrieved on: 
Wednesday, June 2, 2021

Mineral Ice's 10% Menthol formulation delivers maximum strength pain relief in a new, easy to apply, quick-dry foam.

Key Points: 
  • Mineral Ice's 10% Menthol formulation delivers maximum strength pain relief in a new, easy to apply, quick-dry foam.
  • Acquired by Crown three years ago, the Mineral Ice brand has a rich heritage and continues to be a trusted name in pain relief.
  • By leveraging the benefits of the maximum allowable strength of 10% Menthol, our new Mineral Ice Quick Dry Foam provides even more of the cooling and deep soothing relief for minor muscle aches and joint pain that consumers have depended upon for years.
  • Mineral Ice Quick Dry Foam is now available on Amazon.

Lazarus Naturals Introduces CBD Muscle Gel to Bring Pain Relief to Aching Muscles

Retrieved on: 
Wednesday, May 19, 2021

b'Lazarus Naturals , a leader in the CBD category, announces its newest product, CBD Muscle Gel, offering the cooling properties of menthol along with high-potency, full-spectrum CBD.

Key Points: 
  • b'Lazarus Naturals , a leader in the CBD category, announces its newest product, CBD Muscle Gel, offering the cooling properties of menthol along with high-potency, full-spectrum CBD.
  • View the full release here: https://www.businesswire.com/news/home/20210519005330/en/\nNew CBD Muscle Gel is naturally scented with lemon, orange, sweet basil and eucalyptus, along with functional ingredients like menthol and capsaicin.
  • \xe2\x80\x9cOur Muscle Gel uses cooling agents like menthol for immediate pain relief and then the power of CBD kicks in for anti-inflammatory control.
  • The product is available to purchase at www.lazarusnaturals.com or at select retailers.\nJust like every product from Lazarus Naturals, the CBD Muscle Gel is third-party tested for potency, pesticides and heavy metals.

REPEAT --TAAT™ E-Commerce Launching Wednesday February 17, Availing Original, Smooth, and Menthol to Majority of Smokers Aged 21+ Across the U.S.

Retrieved on: 
Tuesday, February 16, 2021

Through the Companys online shop, cartons of TAAT Original, Smooth, and Menthol can be purchased by smokers aged 21+ and shipped to addresses in eligible1 jurisdictions.

Key Points: 
  • Through the Companys online shop, cartons of TAAT Original, Smooth, and Menthol can be purchased by smokers aged 21+ and shipped to addresses in eligible1 jurisdictions.
  • As of December 2020, TAAT is available in chain and independent tobacco retailers across the state of Ohio, with successful performance to date.
  • In a press release dated January 12, 2021, the Company also announced that TAAT Menthol was the first variety to be sold out and reordered.
  • Through a combination of online, in-store, and digital out-of-home campaigns targeted towards smokers aged 21+, the Company has cultivated considerable interest in TAAT across the United States.

TAAT™ E-Commerce Launching Wednesday February 17, Availing Original, Smooth, and Menthol to Majority of Smokers Aged 21+ Across the U.S.

Retrieved on: 
Friday, February 12, 2021

Through the Companys online shop, cartons of TAAT Original, Smooth, and Menthol can be purchased by smokers aged 21+ and shipped to addresses in eligible1 jurisdictions.

Key Points: 
  • Through the Companys online shop, cartons of TAAT Original, Smooth, and Menthol can be purchased by smokers aged 21+ and shipped to addresses in eligible1 jurisdictions.
  • As of December 2020, TAAT is available in chain and independent tobacco retailers across the state of Ohio, with successful performance to date.
  • In a press release dated January 12, 2021, the Company also announced that TAAT Menthol was the first variety to be sold out and reordered.
  • Through a combination of online, in-store, and digital out-of-home campaigns targeted towards smokers aged 21+, the Company has cultivated considerable interest in TAAT across the United States.

Avenue Therapeutics Provides Regulatory Update for IV Tramadol

Retrieved on: 
Thursday, December 17, 2020

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today provided a regulatory update following receipt of the official meeting minutes from a November 2020 Type A meeting with the U.S. Food and Drug Administration (FDA) relating to a path forward for IV tramadol.

Key Points: 
  • NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today provided a regulatory update following receipt of the official meeting minutes from a November 2020 Type A meeting with the U.S. Food and Drug Administration (FDA) relating to a path forward for IV tramadol.
  • Avenue had requested this Type A meeting to address a Complete Response Letter (CRL) it received from the FDA regarding the New Drug Application (NDA) for IV tramadol.
  • Avenue intends to resubmit the NDA in February 2021, barring any Covid-19 related or other setbacks.
  • Avenue Therapeutics is a specialty pharmaceutical company whose mission is to develop IV tramadol, a potential alternative that could reduce the use of conventional opioids, for patients suffering from acute pain in the U.S. Avenue is headquartered in New York City and was founded by Fortress Biotech, Inc. (NASDAQ: FBIO).

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fortress Biotech, Inc. (FBIO)

Retrieved on: 
Wednesday, December 16, 2020

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On October 12, 2020, Avenue disclosed receipt of a Complete Response Letter ("CRL") from the FDA regarding the NDA for its IV Tramadol product.
  • If you purchased or otherwise acquired Fortress securitiesduring the Class Period, you may move the Court no later than January 26, 2021 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fortress Biotech, Inc. (FBIO)

Retrieved on: 
Wednesday, December 9, 2020

Investors suffering losses on their Fortress investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .

Key Points: 
  • Investors suffering losses on their Fortress investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • On October 12, 2020, Avenue disclosed receipt of a Complete Response Letter ("CRL") from the FDA regarding the NDA for its IV Tramadol product.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Building Out Global IP Assets: Taat Seeks to Expand Intellectual Property Portfolio with 17 Trademark Applications Filed in 15 Jurisdictions

Retrieved on: 
Wednesday, October 21, 2020

Beyond Tobacco, which is to be offered in Original and Menthol varieties, is designed to closely emulate every aspect of smoking a traditional cigarette.

Key Points: 
  • Beyond Tobacco, which is to be offered in Original and Menthol varieties, is designed to closely emulate every aspect of smoking a traditional cigarette.
  • The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration.
  • As each individual is different, the benefits, if any, of taking the Companys products will vary from person to person.
  • Disclosures relating to investor relations firms retained by Taat Lifestyle & Wellness Ltd. can be found under the Company's profile on http://sedar.com .

“A Transformational Development”: Video Statement from Taat CEO Details Potential Opportunities with Hong Kong Financier

Retrieved on: 
Tuesday, October 13, 2020

Beyond Tobacco, which is to be offered in Original and Menthol varieties, is designed to closely emulate every aspect of smoking a traditional cigarette.

Key Points: 
  • Beyond Tobacco, which is to be offered in Original and Menthol varieties, is designed to closely emulate every aspect of smoking a traditional cigarette.
  • The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration.
  • As each individual is different, the benefits, if any, of taking the Companys products will vary from person to person.
  • Disclosures relating to investor relations firms retained by Taat Lifestyle & Wellness Ltd. can be found under the Company's profile on http://sedar.com .

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

Retrieved on: 
Monday, October 12, 2020

NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Companys New Drug Application (NDA) for IV tramadol.

Key Points: 
  • NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Companys New Drug Application (NDA) for IV tramadol.
  • Specifically, if a patient requires an analgesic between the first dose of IV tramadol and the onset of analgesia, a rescue analgesic would be needed.
  • Other than this potential safety concern, the FDA did not identify a safety signal in Avenues clinical development program.
  • We firmly stand behind the safety data in our NDA and the ultimate approvability of IV tramadol, said Lucy Lu, MD, President and Chief Executive Officer of Avenue Therapeutics.